[DOI] [PubMed] [Google Scholar] 51.He L, Feng D, Guo H, Zhou Y, Li Z, Zhang K, et al
Q: What is the biggest safety mistake
The FDAs Pharmacy Compounding Advisory Committee is scheduled to review their Category 1 eligibility in July 2026
Do not shake Label with reconstitution date, compound name, and concentration Storage After Reconstitution Both lyophilized powders: 24 months at -20C, protected from light Reconstituted Tesamorelin: 14 days at 2 to 8C under sterile conditions Reconstituted Ipamorelin: 14 days at 2 to 8C under sterile conditions Do not freeze reconstituted solutions Do not mix reconstituted compounds in the same vial unless your protocol requires pre-mixed administration and you have verified stability Regulatory Context Tesamorelin Regulatory Status Tesamorelin is FDA approved as Egrifta for HIV-associated lipodystrophy
Reconstitution and administration determine whether the intended protocol is being delivered
- Plays a role in detoxification, anti-aging, inflammation control, liver protection, and cognitive health
